Journal article
Functions of the Alzheimer’s Disease Protease BACE1 at the Synapse in the Central Nervous System
KM Munro, A Nash, M Pigoni, SF Lichtenthaler, JM Gunnersen
Journal of Molecular Neuroscience | SPRINGERNATURE | Published : 2016
Abstract
Inhibition of the protease β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) is a promising treatment strategy for Alzheimer’s disease, and a number of BACE inhibitors are currently progressing through clinical trials. The strategy aims to decrease production of amyloid-β (Aβ) peptide from the amyloid precursor protein (APP), thus reducing or preventing Aβ toxicity. Over the last decade, it has become clear that BACE1 proteolytically cleaves a number of substrates in addition to APP. These substrates are not known to be involved in the pathogenesis of Alzheimer’s disease but have other roles in the developing and/or mature central nervous system. Consequently, BACE inhibition and kn..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
K. M. Munro is supported by National Health and Medical Research (NHMRC)-Australian Research Council (ARC) Dementia Research Development Fellowship 1100324. Work in the Gunnersen lab is supported by NHMRC Project Grant 1058672. Work in the Lichtenthaler lab is supported by the Deutsche Forschungsgemeinschaft (FOR 2290), the Center for Excellence in Neurodegeneration (CoEN), the Breuer Foundation research award and the Agency for Innovation by Science and Technology (IWT).